List of works - Garth Powis

A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.

scientific article published on 4 November 2014

AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer

scientific article published on 20 March 2012

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

scientific article published on March 2004

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase ⬇️

scientific article published on November 11, 2010

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

scientific article

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling

scientific article published on 17 March 2016

Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma

scientific article

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain

scientific article published on 19 August 2009

Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth

scientific article published on January 2004

Development of sulfonamide AKT PH domain inhibitors ⬇️

scientific article published on March 15, 2011

Discovery of a novel class of AKT pleckstrin homology domain inhibitors

scientific article

Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

scientific article

ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation

scientific article published on 17 May 2016

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

scientific article

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

scientific article published on 04 May 2016

HAF : the new player in oxygen-independent HIF-1alpha degradation

scientific article published on May 2009

HIF-1 regulation: not so easy come, easy go

scientific article

HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance

scientific article published on March 2011

HIF-1alpha and cancer therapy

scientific article published on January 2010

HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer

scientific article

Hypoxia inducible factor as a cancer drug target

scientific article published on December 2003

Hypoxia inducible factor-1alpha as a cancer drug target

scientific article

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer

scientific article published on 30 April 2013

Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation

scientific article published on 06 October 2008

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

scientific article published on October 2006

IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes

scientific article

Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM ⬇️

scientific article published on April 1, 2011

Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer

scientific article

Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells ⬇️

scientific article published on January 24, 2012

Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase

scientific article

Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems

scientific article

In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA.

scientific article

In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.

scientific article

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

scientific article

Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis

scientific article published on July 2003

Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival

scientific article published in July 2003

Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues

scientific article (publication date: 1994)

Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse

scientific article

Inhibiting PI-3-K for glioma therapy

scientific article

Inhibiting the hypoxia response for cancer therapy: the new kid on the block

scientific article published on 29 September 2009

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

scientific article published on 20 February 2010

Integrating whole transcriptome sequence data and public databases for analysis of somatic mutations in tumors.

scientific article published on 19 September 2011

Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo

scientific article

Modeling of Patient-Derived Xenografts in Colorectal Cancer

scientific article

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha

scientific article published on January 2008

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor

scientific article

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

scientific journal article

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

scientific article

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

scientific article published on January 2009

Natural product based inhibitors of the thioredoxin-thioredoxin reductase system

scientific article published on 11 May 2004

Novel Water-Soluble Diorganyl Tellurides with Thiol Peroxidase and Antioxidant Activity

scientific article

OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells

scientific article published on 18 April 2006

Passing the baton: the HIF switch ⬇️

scientific article published on July 18, 2012

Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

scientific article published on January 2009

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

scientific article

Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer

scientific article

Proceedings of the Oxygen Homeostasis/Hypoxia Meeting

scientific article published in May 2004

Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer

scientific article

Recent development of anticancer therapeutics targeting Akt.

scientific article published on January 2011

Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif

scientific article

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

scientific article published on 18 December 2012

Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues

scientific article published on April 2003

Stability of phosphoprotein as a biological marker of tumor signaling

scientific article published in June 2005

Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells

scientific article published on 24 December 2008

Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system

scientific article published on 28 September 2005

Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin

scientific article published on 14 June 2004

Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer

scientific article published on 28 October 2016

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

scientific article published on January 2009

The Hypoxia-Associated Factor Switches Cells from HIF-1α- to HIF-2α-Dependent Signaling Promoting Stem Cell Characteristics, Aggressive Tumor Growth and Invasion ⬇️

scientific article published on April 21, 2011

The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men ⬇️

scientific article published on August 21, 2012

The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice

scientific article

The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response

scientific article published on June 2007

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma

scientific article

The biological effects of isoform-specific PI3-kinase inhibition

scientific article published on January 2010

The hypoxic inducible stress response as a target for cancer drug discovery

scientific article published on August 2006

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

scientific article

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

scientific article

The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis

scientific article published in September 2002

The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells

scientific article

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

scientific article published on April 2009

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

scientific article

The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.

scientific article published in March 2003

Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds

scientific article published on June 2006

Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells ⬇️

scientific article published on November 17, 2003

Thioredoxin signaling as a target for cancer therapy

scientific article published on 3 July 2007

Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity

scientific article published on September 2004

Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice

scientific article published on July 2010

Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium ⬇️

scientific article published on June 1, 2012

Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells

scientific article published on June 2004

List of works by Garth Powis

A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.

AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase ⬇️

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling

Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain

Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth

Development of sulfonamide AKT PH domain inhibitors ⬇️

Discovery of a novel class of AKT pleckstrin homology domain inhibitors

Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

HAF : the new player in oxygen-independent HIF-1alpha degradation

HIF-1 regulation: not so easy come, easy go

HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance

HIF-1alpha and cancer therapy

HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer

Hypoxia inducible factor as a cancer drug target

Hypoxia inducible factor-1alpha as a cancer drug target

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer

Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes

Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM ⬇️

Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer

Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells ⬇️

Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase

Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems

In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA.

In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis

Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival

Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues

Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse

Inhibiting PI-3-K for glioma therapy

Inhibiting the hypoxia response for cancer therapy: the new kid on the block

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Integrating whole transcriptome sequence data and public databases for analysis of somatic mutations in tumors.

Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo

Modeling of Patient-Derived Xenografts in Colorectal Cancer

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

Natural product based inhibitors of the thioredoxin-thioredoxin reductase system

Novel Water-Soluble Diorganyl Tellurides with Thiol Peroxidase and Antioxidant Activity

OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells

Passing the baton: the HIF switch ⬇️

Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer

Proceedings of the Oxygen Homeostasis/Hypoxia Meeting

Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer

Recent development of anticancer therapeutics targeting Akt.

Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues

Stability of phosphoprotein as a biological marker of tumor signaling

Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells

Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system

Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin

Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

The Hypoxia-Associated Factor Switches Cells from HIF-1α- to HIF-2α-Dependent Signaling Promoting Stem Cell Characteristics, Aggressive Tumor Growth and Invasion ⬇️

The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men ⬇️

The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice

The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma

The biological effects of isoform-specific PI3-kinase inhibition

The hypoxic inducible stress response as a target for cancer drug discovery

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis

The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells